OakChart

Trex Bio Inc

TRXBHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 10:47 AM ET

13.51-0.74 (-5.19%)
2026-11-12 16:49 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

TRXB against its 20-day averages
20
Patternshover a marker to name it
EPS mean, own scalesmoothed
RS 100EPS -0.74Price-0.7413.0014.0015.0016.00629K1.3MVolumeOct 26Nov 26TRXBclose 13.5120-day 13.9413.5152w high52w low

18.4% under the 52-week high of 16.56 on 21 Oct 2026. 52-week low 12.50 on 4 Nov 2026. Last 15 sessions, 24.0% high to low. This session is unfinished.

Volume 0.09× normal · the line is the 50-bar volume average

Profile

TRXB
52-week range, 25% of the way up
12.5016.56

Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.

IPOOct 09, 2026
ATR, 14d1.17
Rel volume0.09
Short float1.29%
Insider own55.62%
Inst own4.58%

Snapshot

6 groups

Valuation

Index-
Market Cap370.79M
Enterprise Value-
Income-
Sales-
Book/sh-
Cash/sh-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOOct 09, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C-
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio-
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / No

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.74
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own55.62%
Insider Trans1.81%
Inst Own4.58%
Inst Trans24.37%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.08%
SMA50-2.97%
SMA200-2.97%
Trades-

Technical

Shs Outstand27.45M
Shs Float12.18M
Short Float1.29%
Short Ratio0.99
Short Interest0.16M
52W High16.56 -18.42%
52W Low12.50 8.08%
Volatility11.04% 8.89%
ATR (14)1.17
RSI (14)48.12
Beta-
Rel Volume0.09
Avg Volume159.22K
Volume3,311

Performance

Perf Week4.00%
Perf Month0.07%
Perf Quarter-
Perf Half Y-
Perf YTD0.07%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price29.25
Prev Close14.25
Price13.51
Change %-5.19%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Nov 03, 2026InitiatedSStifelBuy$39+188.7%
Nov 03, 2026InitiatedJJP MorganOverweight$20+48.0%
Nov 03, 2026InitiatedCCantor FitzgeraldOverweight
Nov 02, 2026InitiatedWWedbushOutperform$30+122.1%

Peers

Mkt cap
TickerCompanyMkt cap
NKTRNektar Therapeutics1.30B
ANABAnaptysBio Inc1.45B
QTTBQ32 Bio Inc266.17M
COYACoya Therapeutics Inc73.31M
EVMNEvommune Inc293.97M
ALMSAlumis Inc873.06M
UPBUpstream Bio Inc159.50M
ZURAZura Bio Ltd120.89M
ORKAOruka Therapeutics Inc7.07B
CNTBConnect Biopharma Holdings Ltd42.34M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Alexandria Venture Investments10% OwnerOct 13 '26Buy14.00178,5712,499,9941,346,501Oct 15 04:33 PM
SVLSF VI, LLC10% OwnerOct 08 '26Buy14.0092,8571,299,998214,869Oct 13 04:30 PM

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-24.100--0.00--
2026Q3---0.738--0.004
2026Q4---0.572--0.005
2027Q1---0.540--0.003
2027Q2---0.580--0.003
2027Q3---0.480--0.003
2027Q4---0.487--0.003
2028Q1---0.433---1
2028Q2---0.464---1
2028Q3---0.514---1
2028Q4---0.555---1
2029Q1---0.590---1
2029Q2---0.615---1
2029Q3---0.585---1
2029Q4---0.589---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-023000.000.000.00
2026Q3S2026-10-301000.000.000.00
2026Q3R2026-11-02200-0.62-0.74-0.49
2026Q3R2026-10-30100-0.49-0.49-0.49
2026Q3E2026-11-02400-0.74-0.90-0.47
2026Q3E2026-10-30100-0.47-0.47-0.47

Estimate history

EPS, annual
Period
EPS, quarterly
Period
Sales, annual
Period
Sales, quarterly
Period
Shares, annual
Period
Shares, quarterly
Period

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.29%0.2M12.2M175.61K
2026-10-151.61%0.2M12.2M412.24K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-16SCHEDULE 13DSEC
2026-10-16SCHEDULE 13GSEC
2026-10-16SCHEDULE 13DSEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-15SCHEDULE 13GSEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-138-KCurrent report2026-10-13SEC
2026-10-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-09424B4SEC
2026-10-08EFFECTEffectiveness filing by commission orderSEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-08CERTSEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-103.80M200
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
-

OakChart. TRXB. Cached 15 minutes.

Some panels did not load: news.